【代谢紊乱生物技术公司Vogenx(VOGX.US)IPO定价11-13美元/股 拟募资7500万美元】智通财经APP获悉，专注于开发内分泌和代谢紊乱疾病疗法、正处于2b期临床阶段的生物技术公司Vogenx(VOGX.US)于周三公布了其首次公开募股(IPO)条款。这家总部位于北卡罗来纳州罗利市的公司计划通过以每股11至13美元的价格区间发行630万股股票，募集7500万美元资金。按拟议区间中点计算，Vogenx的完全稀释后市值将达到1.73亿美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.